REFERENCES
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695.
- Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophages foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 1999; 37: 777–787.
- Aikawa M, Libby P. The vulnerable atherosclerotic plaque. Pathogenesis and therapeutic approach. Cardiovasc Pathol 2004; 13: 125–138.
- Faviou E, Vourli G, Nounopoulos C, Zachari A, Dionyssiou-Asteriou A. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in the diagnosis and estimation of severity of coronary artery disease. Free Radic Res 2005; 39: 419–429.
- Toshima S, Hasegawa A, Kurabayashi M et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2243–2247.
- Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary artery disease events in apparently healthy, middle-aged men from the general population. Circulation 2005; 112: 651–657.
- Leonarduzzi G, Chiarpotto E, Biasi F, Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol Nutr Food Res 2005; 49: 1044–1049.
- Holvoet P, Perez G, Zhao Z, Browers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995; 95: 2611–2619.
- Garcia-Cruset S, Carpenter KLH, Codony R, Guardiola F. Cholesterol oxidation products and atherosclerosis. In: Guardiola F, Dutta PC, Codony R, Savage GP. (eds) Cholesterol and phytosterol oxidation products: analysis, occurrence, and biological effects. Champaigne, IL: AOCS Press, 2002; 241-277.
- Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6–11.
- Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002; 160: 91–102.
- Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191–203.
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
- Chang YH, Abdalla DSP, Sevanian A. Characterization of cholesteroloxidation products formed by oxidative modification of low density lipoprotein Free Radic Biol Med 1997; 23: 202–214.
- Tsuchida M, Miura T, Mizutani K, Aibara K. Fluorescence substances in mouse and human sera as a parameter of in vivo lipid peroxidation. Biochim Biophys Acta 1985; 834: 196–204.
- Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2003; 84: 1381–1478.
- Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? J Am Coll Cardiol 2006; 48: 973–979.